Clinical observations indicate that the paramedian region of the thalamus is a critical node for controlling wakefulness. However, the specific nucleus and neural circuitry for this function remain unknown. Using in vivo fiber photometry or multichannel electrophysiological recordings in mice, we found that glutamatergic neurons of the paraventricular thalamus (PVT) exhibited high activities during wakefulness. Suppression of PVT neuronal activity caused a reduction in wakefulness, whereas activation of PVT neurons induced a transition from sleep to wakefulness and an acceleration of emergence from general anesthesia. Moreover, our findings indicate that the PVT-nucleus accumbens projections and hypocretin neurons in the lateral hypothalamus to PVT glutamatergic neurons' projections are the effector pathways for wakefulness control. These results demonstrate that the PVT is a key wakefulness-controlling nucleus in the thalamus.
P atients with occlusion of the paramedian thalamic artery, which results in localized injury to the paramedian region of the thalamus, show disturbances of consciousness ranging from hypersomnolence to sleep-like coma when injuries are bilateral (1-4), a clinical feature not observed in other thalamic injuries (2) . The homologous area of the primate paramedian thalamus in rodents consists of a large number of nuclei, including the paraventricular thalamus (PVT), nucleus reuniens, mediodorsal nucleus, and interanteromedial thalamic nucleus (5, 6) . These nuclei have distinct input and output connections (6) (7) (8) and participate in various brain functions (5, 9, 10) . However, the specific nucleus and circuitry controlling wakefulness have not yet been identified.
We began by visualizing an unbiased map of c-fos expression in the paramedian thalamus after a period of wakefulness or sleep in mice.
We observed a higher level of c-fos expression in the PVT than in the other nuclei of the paramedian thalamus at zeitgeber time 18 (ZT 18; 24:00) and after extended wakefulness ( fig. S1 ). To further examine the in vivo dynamics of PVT neurons during the sleep-wake cycle, we injected adeno-associated virus (AAV) expressing the genetically encoded Ca 2+ sensor GCaMP6f under the control of the CaMKIIa promoter (PVT neurons are primarily glutamatergic neurons) (11) into the PVT ( fig. S2, A and B) . The population Ca 2+ activity was significantly higher during wakefulness than during sleep. The population Ca 2+ activity of the PVT began to increase ahead of signs of behavioral arousal (fig. S2, C to H). We next performed in vivo multichannel electrophysiological recordings to monitor the spike firing of individual PVT neurons in freely behaving mice (Fig. 1A) . The vast majority (20/22) of PVT neurons exhibited a higher firing rate during wakefulness than during sleep (Fig. 1, B and C). The PVT firing rate gradually decreased before sleep onset and increased during transitions from sleep to wakefulness. At the onset of behavioral arousal from non-rapid eye movement (NREM) sleep, the mean firing rate reached 7.1 Hz (Fig. 1, D to F) . In a considerable fraction of neurons (25%), the firing rate exceeded 10 Hz ( fig. S3 ). The increase of PVT neuronal firing occurred briefly before both cortical activation (1.0 ± 0.3 s) and behavioral arousal (1.4 ± 0.3 s).
We next determined the necessity of PVT activity for wakefulness by inhibiting PVT glutamatergic neurons chemogenetically with AAV encoding engineered G i -coupled hM4D receptor (AAV-CaMKIIa-hM4D-mCherry) (Fig. 1G) . Wholecell recordings of PVT neurons from acute brain slices confirmed that clozapine-N-oxide (CNO, 5 mM) potently inhibited hM4D-expressing PVT neurons ( fig. S4 ). At the beginning of the dark phase (ZT 12; 18:00), CNO injection induced a significant reduction in wakefulness relative to the mCherry and saline controls (Fig. 1, H and I, and fig. S6A ), which was primarily due to shortened duration of wakefulness episodes and increased sleep episodes ( fig. S5 ). In addition, spectral analysis of electroencephalography (EEG) showed that CNO injection increased the high delta power (2 to 4 Hz) of wakefulness at hour 2 after CNO injection (figs. S6 and S7). Note that inhibition of the PVT increased the number of micro-arousals ( fig. S8, A and B) , which might result from a fragmentation of wakefulness. In contrast, CNO injection at the beginning of the light phase (ZT 0; 6:00) did not further reduce wakefulness ( fig. S9, A, D , and G). The EEG power spectrum for each state and the number of micro-arousals during the light phase were not affected by CNO injection (figs. S8C and S9).
We next explored the role of the PVT in controlling wakefulness by ablating PVT glutamatergic neurons. We injected a mixture of AAV encoding diphtheria toxin A (AAV-DIO-DTA) and AAV-CaMKIIa-Cre-GFP into the PVT. PVT glutamatergic neurons were selectively ablated after 4 weeks of virus injection ( fig. S10A ). Animals with chronic PVT lesion showed a decrease of wakefulness during the dark phase, with a reduction in duration of wakefulness episodes and an increase in NREM sleep episodes and micro-arousals, whereas lesion of the PVT did not affect wakefulness during the light phase ( fig. S10 , B to G). DTA lesion increased the EEG high delta power (2 to 4 Hz) of wakefulness during the dark phase. This lesion also caused an increase in the low theta power (4 to 7 Hz) (fig. S10, H to L), which might reflect a compensatory mechanism during chronic ablation of neurons induced by DTA. In addition, we also injected ibotenic acid to rapidly ablate PVT neurons within several days (Fig. 1J and  fig. S11A ). Acute PVT lesion reduced wakefulness during the dark phase but did not affect wakefulness during the light phase ( Fig. 1K and fig.  S11 , B and C). Lesion of the PVT caused fragmentation of wakefulness, which was indicated by shortened duration of wakefulness episodes and by increased sleep bouts and micro-arousals during the dark phase. In contrast to chronic lesion, ibotenic acid lesion increased the EEG high delta power (2 to 4 Hz) but not the theta power, indicating a more typical damage to the wakefulness state (Fig. 1L, fig. S11 , D to J, and movie S1).
We then used optogenetics to examine the causal role of the PVT in wakefulness control. We injected AAV expressing channelrhodopsin 2 (AAV-CaMKIIa-ChR2-mCherry) into the PVT ( Fig. 2A ). Functional expression of ChR2 was verified by in vitro electrophysiology (Fig. 2B ). We applied optical stimulation (lasting 20 s) after the onset of stable NREM or REM sleep during the light phase. Optical stimulation of PVT glutamatergic neurons during NREM sleep reliably induced transitions to wakefulness in a frequency-dependent manner (Fig. 2, C and D) . Optical stimulation of the PVT at a shorter duration (lasting 5 s) was still sufficient to induce such transitions ( fig. S12 ). Optical stimulation also induced transitions to wakefulness from REM sleep ( fig. S13, A and B) . Optical stimulation significantly increased the probability of wakefulness, along with a complementary decrease of both NREM and REM sleep probability, relative to the mCherry control ( Fig. 2E  and fig. S13, C and D overt increase in wakefulness with a decrease of EEG delta power ( fig. S14 , B to F).
To investigate whether activation of PVT neurons is sufficient to induce wakefulness from an unconscious state-a typical feature of patients with paramedian thalamic stroke (4)-we optically activated PVT neurons in mice under general anesthesia induced by isoflurane (Fig. 2F) . When a stable EEG burst-suppression mode (a marker of anesthetic depth) (12) was observed, 10-Hz stimulation (lasting 20 s) caused an immediate increase in total EEG burst activity. The increase in burst activity was accompanied by a prolonged burst duration, a decreased burst suppression ratio, and an altered EEG spectrum (Fig. 2, G to J) . Interestingly, a peak at approximately 10 Hz appeared in the EEG spectrum with optical stimulation (Fig. 2J) , which might reflect that optogenetic stimulation at 10 Hz causes prominent 10-Hz oscillations in cortex. Additionally, sustained activation of PVT neurons significantly accelerated the emergence from isoflurane-induced unconsciousness, which was not observed in mCherry mice (Fig. 2K) .
Recent studies have reported that thalamic nuclei directly regulate the activities of cortical neurons (13, 14) . The PVT also sends brainwide projections, including direct projections to the cortex (15) . Thus, we next searched for the PVT downstream pathways mediating the wakefulness-maintaining effects. ChR2-mCherry expression indicated that PVT glutamatergic neurons send projections to multiple cortical regions, including the medial prefrontal cortex (mPFC) and insular cortex ( fig. S15, A to D) . The PVT sends dense projections to the nucleus accumbens (NAc) (Fig. 3D) , which participates in wakefulness control (16) . Bilateral optical stimulation of PVT projections to different layers or subregions of the prelimbic cortex of the mPFC failed to induce rapid transitions from NREM sleep to wakefulness. Optical stimulation of PVT axonal terminals in other cortical regions, including the cingulate cortex and infralimbic cortex of the mPFC or the anterior and posterior part of the insular cortex, had no obvious effects on sleep-wake transition (Fig. 3, A to C, and fig.  S15 , E and F), although the paramedian thalamus can excite these cortices via glutamatergic connections (17) . Moreover, chemogenetic inhibition of the mPFC-projecting PVT neurons also did not affect the time spent in wakefulness ( fig. S16) . Together, our results do not sufficiently support a crucial role of the PVT-cortex pathway in controlling wakefulness. However, optical stimulation of the PVT-to-NAc projections reliably elicited transitions to wakefulness from both NREM and REM sleep (Fig. 3E) . In vitro ChR2-assisted circuit mapping (18) confirmed this functional monosynaptic connection (Fig. 3F) , indicating that a direct PVT-NAc pathway may mediate the observed transitions. In addition, chemogenetic inhibition of NAc-projecting PVT neurons significantly reduced wakefulness (Fig. 3,  G to I) . The importance of this pathway in wakefulness control was further confirmed by the compromised wakefulness-inducing effects of the PVT after ablation of NAc neurons using ibotenic acid ( fig. S17) . Manipulation of the PVT-NAc pathway efficiently reproduced the wakefulnesscontrolling effects of the PVT (fig. S18) .
Because the PVT receives inputs from the brainstem and lateral hypothalamus (LH) (19, 20) , we next searched for the upstream pathway that modulates its wakefulness-maintaining function. We used Cre-dependent rabies virus-mediated monosynaptic retrograde tracing in vGlut2-Cre mice and found that PVT glutamatergic neurons received direct inputs from LH hypocretin (Hcrt) neurons ( fig. S19 ), which are involved in wakefulness control (21) . We specifically suppressed inputs from Hcrt neurons by expressing AAV-DIO-hM4D-mCherry in the LH of Hcrt-Cre mice and locally applying CNO (5 mM) in the PVT (Fig. 4A) . CNO infusion significantly decreased wakefulness, accompanied by fragmentation of wakefulness (Fig. 4, B and C, and fig. S20, A to D) . Moreover, inhibition of this pathway shortened NREM sleep latency and increased the number of NREM sleep episodes ( fig. S20, E and F) .
We then examined the sufficiency of these inputs for wakefulness control. Optical stimulation (20 Hz) of Hcrt neurons' terminals during NREM sleep significantly increased the firing rate of PVT neurons (Fig. 4, D and E to wakefulness occurred after stimulation of the LH Hcrt -PVT pathway (Fig. 4, F and G, and fig.  S21 ). Optogenetic stimulation of Hcrt neurons' terminals in the PVT could still induce transitions from sleep to wakefulness after blockade of the potential antidromic action potentials by injection of muscimol into the LH ( fig. S22 ). Such wakefulness-controlling effects were partially attenuated by the Hcrt receptor 2 antagonist TCS-OX2-29 (Fig. 4H) . To further confirm the importance of the LH Hcrt -PVT pathway in controlling wakefulness, we injected viruses expressing hM3D into the LH and hM4D into the PVT, respectively ( fig. S23, A and B) . Stimulation of Hcrt neurons increased the amount of wakefulness, whether or not the PVT was chemogenetically inhibited ( fig. S23C ). These unexpected results might be because the activity of the PVT was not completely suppressed under the condition of activating Hcrt neurons' terminals. Alternatively, after ablating PVT neurons using caspase-3, the latency to wakefulness with optogenetic stimulation of Hcrt neurons increased, confirming an important role of the LH Hcrt -PVT pathway in wakefulness control ( fig. S23 , D to G). Recently, the PVT in the paramedian thalamus has been extensively studied because of its involvement in multiple behaviors, including fear conditioning (22, 23) , drug addiction (24, 25) , and feeding (26) , all of which require elevated wakefulness. Our results demonstrate that the PVT is both necessary and sufficient for the control of wakefulness, and further reveal the important role of the LH Hcrt -PVT-NAc pathway in the control of wakefulness (Fig. 4I) . These results provide experimental evidence supporting the PVT as a critical thalamic node in the wakefulnesscontrolling neural network.
